SESSION IX: INDOLENT B-CELL LYMPHOMA 

Session Chairs: Brian Hill and Tara Graff

Approach to Untreated Follicular Lymphoma, Where Are We Now and Future Directions | Brian T Hill, MD, PhD | Cleveland Clinic, Cleveland, Ohio, USA

How Should We Risk Stratify and Tailor Therapy for Relapsed/Refractory Indolent Lymphoma?  | Christopher R Flowers, MD, MS | MD Anderson Cancer Center, Houston, Texas, USA

How to Implement the Administration of Bispecifics Into Community Oncology Practice | Tara Graff, DO, MS | Mission Cancer and Blood, Des Moines, Iowa, USA

Accessing Novel Therapies for Indolent Lymphoma in South America | Phillip Scheinberg, MD, PhD | Beneficencia Portuguesa de Sao Paulo, Sao Paulo, Brazil

Oral Abstract | IBCL-523: Comparative Efficacy, Safety, and Cost-Effectiveness of Subcutaneous Versus Intravenous Rituximab in Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis | Khaled Albakri, MS | The Hashemite University, Zarqa, Australia

Oral Abstract | IBCL-541: A Comprehensive Single-Cell Multi-Omic Analysis to Depict the Biological Heterogeneity of Follicular and Large B-Cell Lymphomas | Sofia Huerga-Domínguez, MD | Cancer Center Clínica Universidad de Navarra, Pamplona, Spain